Portfoliotracker

Bioceltix S.A.

BCX.WA · WARSAW · Healthcare Biotechnology 15/100 E

66,50 PLN
▼ −2,30 (−3,34 %)
Trading
Price as of 17. 11. 13:50, fetched 17. 11. 14:07
Next earnings–
Ex-dividend–
Analysts–
50 / 200 day average– / –

Price

Portfoliotracker score15 / 100 Market cap371 mil. PLN P/E– Forward P/E-16,8 P/S– P/B5,5 EV/EBITDA– Dividend yield– FCF yield-5,59 % EPS-3,47 PLN Net margin0,0 % Return on equity-39,4 % Beta0,93 Debt / equity0,00
52-week range 57,50 to 99,00
3-month average volume0,0 M

Finance

Where the revenue goes

Loading the income statement flow…

Fundamentals

Loading key figures…

Insiders, analysts and people

All trades and changes

Loading insiders, analysts and opinions…

Co se právě děje

AI souhrn
Objednat AI souhrn, co se u firmy právě děje Vytvoří se jednou na pozadí a pak ho uvidí všichni. Ve verzi Free 3 objednávky měsíčně.

About the company

Bioceltix S.A. engages in the development of veterinary biologics based on mesenchymal stem cells. The company's products include BCX-CM-J, a stem-cell based medicinal drug for the treatment of osteoarthritis in dogs; BCX-CM-AD, an allogeneic stem cell-based medicinal product for the treatment of atopic dermatitis in dogs; and BCX-EM, an allogeneic stem cell-based medicinal product for the treatment of osteoarthritis in horses. It also develops BCX-CM-Sec, a research project aimed at developing a cell-free biological drug to treat atopic dermatitis in dogs. The company was founded in 2016 and is headquartered in Wroclaw, Poland.

Employees
49
Country
Poland
Data since
8. 11. 2021

Explore further

Similar companies CRI.WASCP.WACBF.WASNT.WADAT.WA

Intraday chart

Your own portfolio, properties and finances in one place.

The account is free with no time limit. Only you see your data; nobody adds it up with others.

This is saved to your account. You can keep browsing, calculating and comparing without signing in.

Welcome back

Sign in and pick up where you left off.

or continue with

No account yet? Create a free account